Promore Pharma
25.10.2021 09:21:54 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / October 25, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
Stockholm 25 October 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announces that a peer-reviewed scientific article describing the results of a clinical study with ropocamptide for the treatment of venous leg ulcers has been published in the journal Wound Repair and Regeneration.
In 2020, Promore Pharma completed a clinical trial, HEAL LL-37, a phase IIb double-blind, randomized, placebo-controlled study aimed at evaluating the efficacy and safety of a new drug, LL-37 / ropocamptide for local administration in combination with compression therapy. The study was performed on 148 patients suffering from difficult-to-heal venous leg ulcers.
Today, the company announces that a scientific article has been published in the journal Wound Repair and Regeneration, which is the journal of the international society in wound care, Wound Healing Society. Co-authors of the article are several internationally renowned subject area experts, including professors Jan Apelqvist, Arkadiusz Jawien, and Folke Sjöberg.
" We are very content that the results of HEAL LL-37 are now published and available to the scientific community and the general public. The publication is a confirmation of the quality of the completed clinical study ", says Jonas Ekblom, CEO of Promore Pharma.
" Once again, we thank all the staff at the healthcare facilities who have participated in the study for their valuable contributions, " says Margit Mahlapuu, CSO of Promore Pharma.
The published article is entitled "Evaluation of LL-37 in Healing of Hard-to-Heal Venous Leg Ulcers: a Multicentric Prospective Randomized Placebo-Controlled Clinical Trial" and can be read in its entirety via the following link:
https://onlinelibrary.wiley.com/doi/full/10.1111/wrr.12977
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
Attachments
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/669452/Promore-Pharma-Announces-that-Scientific-Article-has-Been-Published-on-Clinical-Study-Results-with-Ropocamptide-for-Venous-Leg-Ulcers
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Announces Auditor Review of Q2 Financial Statements26.10.2026 21:30:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / October 26, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTC PINK:CLRMF) announces that, as of October 22, 2026, the Company's auditor, Manning Elliott LLP, has completed a review of the Company's second quarter consolidated interim financial statements for the six-month period ended July 31, 2026 (the "Financial Statements"), which were included in the Company's management information circular dated October 14, 2026, in connection with the Company's upcoming annual general and special meeting scheduled for November 13, 2026. No amendments were made to the Financial Statements as a result of the auditor's review, other than the removal of the "Notice of No Auditor Review." Upcoming Annual General and Special Meeting of Shareholders Additionally, Clean Air Metals' shareholders are reminded that the Annual General and Special Meeting of Shareholders (the "Meeting") will be held virtually on November 13, 2026. S
Miami Fashion Week(R) Celebrates 10 Years With a Landmark Anniversary Edition, October 13-18, 202626.10.2026 15:00:00 CET | Press release
MIAMI, FL / ACCESS Newswire / October 26, 2026 / Miami Fashion Week® (MIAFW) celebrated its landmark 10th anniversary October 13-18, 2026, bringing together international designers, Latin American talent and Miami's creative community for six days of runway presentations, industry programming and special events. The milestone edition celebrated a decade of connecting Miami with the international fashion industry while continuing to expand beyond the runway through sustainability, technology, education and cultural exchange. Further strengthening its ties to the local community, MIAFW established a long-term partnership with Miami Dade College and Miami Fashion Institute. Images: Courtesy of Miami Fashion Week "Celebrating 10 years of Miami Fashion Week is an incredibly meaningful milestone," said Lourdes Fernandez-Velasco, Executive Director of Miami Fashion Week. "Over the past decade, we've built a platform that connects designers, creatives and industry leaders from around the world
Chervon Names Parker Wesley Clary Director of Field Sales - Southern Division26.10.2026 14:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / October 26, 2026 / Parker Wesley Clary joins Chervon as Director of Field Sales - Southern Division, effective October 26, 2026, reporting to Thomas Kentouris, VP of Field Sales. Clary assumes responsibility for the Southern Division of the Chervon Field Sales Team. He is charged with developing a strong organization, building outstanding store-level merchandising and promotional programs. Most recently, Parker was a Key Account Manager for TTI/Milwaukee Pro Tools responsible for the Transportation Maintenance Vertical. His impressive career also includes a series of increasingly responsible positions in store coverage and field sales management. "Parker's exceptional sales and sales management skills will help us deliver our bold growth targets," said Thomas Kentouris. "He is a high-potential talent with a bright future ahead at Chervon." "The opportunity to be a part of Chervon's inspired high-performance culture was most compelling to me," said Par
Chervon names Joel Petersheim as Vice President, End User Research and Sales - OPE Commercial USA26.10.2026 14:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / October 26, 2026 / Joel Petersheim joins Chervon as Vice President, End User Research and Sales - OPE Commercial, effective October 26, 2026, reporting to Joe Galli, CEO. Petersheim brings to Chervon 15+ years of experience at TTI/Milwaukee encompassing a series of increasingly responsible positions in sales, key account management, end user marketing, and sales management. Most recently, he held the position of Vice President Industrial Channel Sales - Northeast. Joel's impressive career also includes a series of director level end user marketing leadership roles focused on the MEP Verticals. His track record in converting key end users and in growing sales in each of his past positions was consistently outstanding. "Joel is a tremendous addition to the outstanding leadership team we are building at Chervon," said Joe Galli. "He is a high potential talent with a tremendous track record of success at the account and end user level." "I am enormously i
Chervon Names Maggie Jones Director of National Field Sales OPS26.10.2026 14:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / October 26, 2026 / Maggie Jones joins Chervon as Director of National Field Sales Operations, effective October 26, 2026, reporting to Thomas Kentouris, VP of Field Sales. Jones will be charged with building out the support system, technology platform, and rigorous measurement/control process for the Chervon Field Sales Network. Most recently, Maggie was Divisional Sales Manager for TTI/Milwaukee where she was responsible for leading 140 field sales store coverage reps. She was an outstanding performer managing the high growth Texas region. Her career also included a series of store coverage and sales management positions in the Southeast USA. "Maggie is best described as an overachieving superstar," said Thomas Kentouris. "Her leadership skills, organization skills, and results orientation will serve her well as she builds our field sales team infrastructure." "I cannot wait to get started supporting Chervon's vision of industry leadership," said Jon
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom